Investigational drug · Phase 3
AD-2282
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Primary Hypercholesterolemia.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
2
Any phase or sponsor naming "AD-2282"
First trial start
2025
Feb 3, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AD-2282", any sponsor or status.
Conditions studied
As listed on its trial records.
- Primary Hypercholesterolemia
Approved drugs for the same conditions: High cholesterol · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "AD-2282" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282Pivotal-lookingCompleted
Addpharma Inc.Industry
NCT06747936 · 129 participants · Start Feb 3, 2025 · Primary completion May 30, 2025
Drug: AD-2281; AD-2282 and 1 more · For: Primary Hypercholesterolemia
Sites: Seoul, South Korea
Addpharma Inc.Industry
NCT06858865 · 60 participants · Start Jul 12, 2025 · Primary completion Aug 14, 2025
Drug: AD-228A; AD-2281 and AD-2282 · For: Primary Hypercholesterolaemia
Sites: Seoul, South Korea
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Primary Hypercholesterolemia
- AD-2281Phase 31 trial
Addpharma Inc. · Primary Hypercholesterolemia
- BR1018APhase 31 trial
Boryung Pharmaceutical Co., Ltd · Essential Hypertension, Primary Hypercholesterolemia
- BR1018A-1Phase 31 trial
Boryung Pharmaceutical Co., Ltd · Essential Hypertension, Primary Hypercholesterolemia
- BR1018BPhase 31 trial
Boryung Pharmaceutical Co., Ltd · Essential Hypertension, Primary Hypercholesterolemia
- BR1018B-1Phase 31 trial
Boryung Pharmaceutical Co., Ltd · Essential Hypertension, Primary Hypercholesterolemia
- BR1018CPhase 31 trial
Boryung Pharmaceutical Co., Ltd · Essential Hypertension, Primary Hypercholesterolemia
- BR1018C-1Phase 31 trial
Boryung Pharmaceutical Co., Ltd · Essential Hypertension, Primary Hypercholesterolemia
- DW5421APhase 31 trial
Daewon Pharmaceutical Co., Ltd. · Primary Hypercholesterolemia, Mixed Dyslipidemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.